Original from: Siemens Healthineers

Siemens Healthineers AG today announces its results for the third quarter, ending June 30, of fiscal year 2023.

Q3 Fiscal Year 2023 

¡¤    Equipment orders clearly exceeded strong equipment revenues on a broad basis; equipment book-to-bill ratio 1.11 

¡¤    Comparable revenue growth very strong at 10.1% excluding rapid COVID-19 antigen tests; taking into account the tailing-off rapid antigen test business, revenue rose by 3.6% on a comparable basis 

¡¤    Imaging showed comparable revenue growth of 15.2%; adjusted EBIT margin of 21.8% clearly above the prior-year quarter 

¡¤    Diagnostics revenue fell by 20.1% on a comparable basis due to tailing-off rapid COVID-19 antigen test business; excluding antigen tests comparable revenue grew 2.0%; adjusted EBIT margin -0.5%; excluding rapid antigen tests and transformation costs 1.0% 

¡¤    Varian showed comparable revenue growth of 6.7%; adjusted EBIT margin 12.1% 

¡¤    Advanced Therapies posted comparable revenue growth of 11.9%; adjusted EBIT margin clearly higher than in the prior-year quarter at 15.3% 

¡¤    Overall adjusted EBIT margin fell slightly to 14.2%, mainly due to drop out of contributions from rapid COVID-19 antigen tests 

¡¤    Adjusted basic earnings per share rose to €0.53

Outlook for Fiscal Year 2023 

We confirm our expectation for comparable revenue growth of -1% to 1% (6% to 8% excluding revenue from rapid COVID-19 antigen tests) and adjusted basic earnings per share of €2.00 to €2.20. 

Bernd Montag, CEO of Siemens Healthineers AG: 

»The Siemens Healthineers team once again delivered a quarter of strong growth. This clearly underlines the special relevance and meaning of our innovations for our customers and their patients worldwide.«

Source: Siemens Healthineers sustains strong revenue momentum in the third quarter